Those included were more likely to be white (P < .0001), to be men who have sex with men (P < .0001), to have higher CD4+ T-cell counts (P < .0001), to have lower viral loads (P < .0001), to be cART naive at the start of TDF therapy (P < .0001), to have started TDF therapy in an earlier year (P < .0001), and to have experienced a previous AIDS-defining event (P = .0003). The gene discussed is CD4; the disease is AIDS.